Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) have been given a consensus recommendation of “Moderate Buy” by the fourteen brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $19.90.

Several brokerages recently commented on ORIC. Wall Street Zen raised shares of Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Thursday, January 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a report on Monday, March 9th. Wedbush reduced their target price on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, April 1st. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $15.00 target price on shares of Oric Pharmaceuticals in a report on Tuesday, February 24th.

Insider Activity at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 52,000 shares of Oric Pharmaceuticals stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total transaction of $702,520.00. Following the completion of the sale, the chief financial officer owned 68,148 shares of the company’s stock, valued at approximately $920,679.48. The trade was a 43.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 6.82% of the company’s stock.

Institutional Trading of Oric Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ORIC. Orbimed Advisors LLC boosted its holdings in shares of Oric Pharmaceuticals by 305.0% during the 3rd quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company’s stock worth $43,701,000 after buying an additional 2,742,475 shares during the period. Paradigm Biocapital Advisors LP acquired a new stake in Oric Pharmaceuticals in the 4th quarter worth about $19,642,000. State Street Corp raised its stake in Oric Pharmaceuticals by 77.1% in the 4th quarter. State Street Corp now owns 4,258,397 shares of the company’s stock worth $34,834,000 after purchasing an additional 1,854,458 shares in the last quarter. Vanguard Group Inc. raised its stake in Oric Pharmaceuticals by 48.8% in the 3rd quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company’s stock worth $55,802,000 after purchasing an additional 1,525,445 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Oric Pharmaceuticals by 3,646.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock worth $13,555,000 after purchasing an additional 1,299,799 shares in the last quarter. Institutional investors own 95.05% of the company’s stock.

Oric Pharmaceuticals Price Performance

Shares of ORIC opened at $8.91 on Tuesday. The firm has a 50-day moving average of $11.43 and a 200-day moving average of $11.28. Oric Pharmaceuticals has a one year low of $3.90 and a one year high of $14.93. The company has a market cap of $894.21 million, a PE ratio of -5.86 and a beta of 1.36.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. Analysts expect that Oric Pharmaceuticals will post -2.17 earnings per share for the current year.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.